What are the clinical complications in post-stroke patients after 90 days?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Clinical complications in post-stroke patients after 90 days commonly include motor deficits, spasticity, post-stroke depression, cognitive impairment, and recurrent stroke risk. These complications can significantly impact the patient's quality of life, morbidity, and mortality. Motor deficits may persist with approximately 50-70% of patients experiencing some degree of hemiparesis, requiring ongoing physical therapy 2-3 times weekly and possibly antispasticity medications like baclofen (10-25mg three times daily) or tizanidine (2-8mg three times daily) for spasticity management, as suggested by the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack 1. Post-stroke depression affects about 30% of survivors and should be treated with SSRIs such as sertraline (50-100mg daily) or escitalopram (10-20mg daily). Cognitive impairments persist in 20-30% of patients, necessitating cognitive rehabilitation. Secondary stroke prevention is crucial through antiplatelet therapy, such as aspirin 81-325mg daily or clopidogrel 75mg daily, but Dual Antiplatelet Therapy (DAPT) is associated with increased risk of bleeding and no benefit in long-term reduction of recurrent stroke risk beyond 90 days after stroke 1. Patients should also be monitored for dysphagia, seizures (occurring in 2-4% of patients), and central post-stroke pain (treated with gabapentin 300-1200mg three times daily or pregabalin 50-300mg twice daily). Aggressive management of hypertension (target <130/80 mmHg), diabetes (HbA1c <7%), and hyperlipidemia (LDL <70 mg/dL) is also essential for secondary stroke prevention. All patients who have had a stroke should have an assessment of their capacity to perform activities of daily living, as recommended by the primary care of adult patients after stroke guideline 1. Regular follow-up and monitoring for these complications can help improve the patient's quality of life, reduce morbidity, and prevent mortality. Key considerations include:

  • Ongoing physical therapy and antispasticity medications for motor deficits
  • SSRI treatment for post-stroke depression
  • Cognitive rehabilitation for cognitive impairments
  • Antiplatelet therapy for secondary stroke prevention
  • Monitoring for dysphagia, seizures, and central post-stroke pain
  • Aggressive management of hypertension, diabetes, and hyperlipidemia.

From the Research

Clinical Complications in Post-Stroke Patients After 90 Days

  • Post-stroke patients may experience various clinical complications, including fatigue, depression, contracture and spasticity, hemiplegic shoulder pain, and central poststroke pain 2.
  • The risk of recurrent stroke is significant, affecting 9% to 15% of people within 1 year 3.
  • Long-term secondary prevention strategies are crucial to reduce the burden of recurrent stroke, including blood pressure management, diabetes control, lipid lowering, and antiplatelet therapy 3, 4.

Management of Post-Stroke Patients

  • Blood pressure lowering treatment to a target of <130/80 mmHg is recommended, except in subgroups at increased risk of harm 3.
  • HMGCoA-reductase inhibitors (statins) and targeting a low-density lipoprotein level of <1.8 mmol/l (70 mg/dl) are recommended for lipid management 3.
  • Antiplatelet therapy with aspirin and clopidogrel is recommended for 21 to 90 days after stroke, but not longer 2, 3.
  • Diabetes management should include a glucagon-like peptide 1 receptor agonist or sodium-dependent glucose cotransporter 2 inhibitor, and aiming for an HbA1c level of <7% is reasonable 2, 3.

Combination Therapy

  • Combination therapy with antiplatelets, angiotensin-converting enzyme (ACE) inhibitors, and statins may have additive protective effects in reducing ischemic stroke severity and tissue at risk 5.
  • ACE inhibitors and angiotensin II receptor antagonists have demonstrated their efficacy in preventing target organ damage and reducing cardiovascular morbidity and mortality in ischemic heart disease 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.